Among the stories on this video edition of LexisNexis Legal News, a majority of Food and Drug Administration advisers voted in mid-July to keep Avandia on the market and Ohio’s Attorney General says AIG has agreed to pay $725 million to resolve a class action brought against it by investors. Stories on this episode: 1. A majority of Food and Drug Administration advisers voted in mid-July to keep Avandia on the market. However, LexisNexis Mealeys Emerging Drugs & Devices Editor Tom Moylan says they split on whether the anti-diabetes drug should carry additional warnings about its heart risks, or that its use be restricted. 2. In its review of a vaccine court case over whether measles-mumps-rubella vaccine causes autism, the Federal Circuit US Court of Appeals recently expressed disapproval of the government’s use of an expert who was for practical purposes unrebuttable, because a British court refused to unseal the data underlying his report. LexisNexis Mealeys vaccines editor Michael Lefkowitz explains. 3. Ohio Attorney General Richard Cordray on July 16 said American International Group has agreed to pay $725 million to resolve a class action brought against it by investors who allege that the company engaged in bid-rigging and accounting improprieties. 4. The Securities & Exchange Commission on July 15th said Goldman Sachs has agreed to pay $550 million in penalties and to change its business practices to settle allegations the company misled investors in a subprime …